Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 – 23 February 2023
EMA’s human medicines committee (CHMP) recommended granting a marketing authorisation for Akeega (niraparib/abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer with BRCA 1/BRCA 2 mutations. The committee adopted a …
See Original Article
Leave a Reply